Staff Scientist
University of Chicago Charter School
About this role
The Reizis Lab at University of Chicago Medicine is seeking a Staff Scientist to investigate the role of DNASE1L3 in immune tolerance and its breakdown in systemic lupus erythematosus (SLE). The position focuses on studying anti-DNASE1L3 antibodies in human SLE patients and mechanisms of autoimmunity in DNASE1L3-deficient mice. The role is embedded within the Section of Rheumatology and supports academic research and publication efforts.
Skills
Qualifications
About University of Chicago Charter School
uchicagocharter.orgN/A
Recent company news
Crain's Chicago BusinessJulie Getzels
1 week ago
University of Chicago NewsLiz Thompson appointed chair of University of Chicago Charter School board
Aug 27, 2015
Chicago TribuneUniversity of Chicago charter school to pay $125,000 to settle suit
Apr 19, 2024
ABC7 ChicagoChicago high school student Julien Sims accepted to 25 colleges earns $1M in scholarships
Apr 18, 2021
Adler PlanetariumChicago’s Black Women in STEAM Series: Meet Sydney
Mar 20, 2019
About University of Chicago Charter School
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for University of Chicago Charter School.
Salary
$80k – $100k
per year
More jobs at University of Chicago Charter School
Similar Jobs
Research Services Entry Laboratory Science Professional
University of Colorado
Key Account Manager*in Immunologie (m/w/d)
GSK plc
Patient Journey Partner Nefrología-Reumatología (Madrid, CLM y Canarias)
Roche
Postdoctoral Scholar
Penn State University
Post Doc Res Assoc
Trinity College
Senior Medical Director, Early R&I Clinical Development, Rheumatology/Clinical Immunology
AstraZeneca